SINO BIOPHARM (01177): MSCI ESG rating upgraded to AA level.

SINO BIOPHARM (01177) announced that the Group's Morgan Stanley Capital International (MSCI) ESG rating has been upgraded from A to AA, making it a global leader in ESG practices among large pharmaceutical companies. In the ESG governance sector, the Group has established and continuously improved an ESG governance system with the board of directors as the highest decision-making body. With the core strategy of "CARE," the Group focuses on disease treatment, pharmaceutical accessibility, win-win relationships, and environmental friendliness, systematically carrying out ESG practices to promote the integration of sustainable development concepts with corporate decisions and operations. In the field of environmental friendliness, the Group has actively responded to the national "3060" dual carbon target and integrated green development concepts into all operational processes. As a green responsible enterprise in the Chinese pharmaceutical industry, the Group has actively promoted specialized work in energy conservation and emission reduction technologies, resulting in a continuous decrease of major pollutant emissions intensity by over 10% annually for the past five years. Additionally, the Group has systematically expanded green energy and implemented low-carbon culture construction practices, aiming to achieve a synchronized decrease in carbon emissions intensity and total emissions by 2025, taking solid steps towards the milestone of "carbon peak." The Group's continuous efforts in green development have been widely recognized, with three member companies receiving the national-level "Green Factory" title. In the area of social responsibility, the Group adheres to the operational concept of "health technology, warming more lives," actively advancing business upgrades, filling clinical gaps, and providing solid guarantees for the health rights of more patients. The Group has increased research and development investment, with research and development expenses totaling over 13 billion RMB in the past three years. The Group has also established an international research and development platform, engaged in a series of precision investment mergers and acquisitions, and signed an exclusive authorization agreement with Sanofi S.A. on loratinib in early 2026 to further promote the benefits of high-quality medical achievements to global patients. Over the past three years, the Group's key products have served more than 160 million patients. The Group places high importance on talent team construction and development, systematically carrying out the "Employee Care Plan (EAP)" and talent development work to promote mutual growth of the company and employees. While continuously improving its own sustainable development capabilities, the Group actively engages in charitable public welfare activities, with cumulative donations exceeding 1.5 billion RMB in the past three years, focusing on disaster relief, rural revitalization, inclusive healthcare, and other areas, demonstrating corporate responsibility. The upgrade of the rating to AA represents MSCI's high recognition of the Group's ESG management level and practical achievements, marking an important milestone in the Group's pursuit of sustainable development and fulfillment of corporate social responsibility. As a leading innovative pharmaceutical enterprise in China Meheco Group, the Group believes that excellent ESG performance is the core support for creating long-term value and achieving high-quality development. Looking ahead, the Group will continue to deepen practices in the dimensions of environment, society, and governance, while leading the industry and promoting coordinated development of the industrial chain, driving the green and high-quality development of China Meheco Group's health industry to create sustainable shared value for all stakeholders and steadily move towards being a global ESG industry benchmark.